NUMI NUMINUS WELLNESS INC.

EQS-News: Proactive research analyst on Numinus Wellness' annual results

EQS-News: Numinus Wellness Inc.
Proactive research analyst on Numinus Wellness' annual results

19.12.2022 / 14:02 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive

Proactive UK Ltd

3


News Source: News Direct

19.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Numinus Wellness Inc.
United States
ISIN: CA67054W1032
EQS News ID: 1516705

 
End of News EQS News Service

1516705  19.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1516705&application_name=news&site_id=research_pool
EN
19/12/2022

Underlying

NUMINUMINUS WELLNESS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUMINUS WELLNESS INC.

 PRESS RELEASE
Free
NUMI NUMINUS WELLNES...

Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering...

Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C. THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today ann...

February 1, 2024 1 EN
Robert Sassoon
  • Robert Sassoon
NUMI NUMINUS WELLNES...

A Quarter of Strong Growth; Focus on Cash Burn Reduction

Strong sequential revenue growth. Numinus’ fiscal third quarter ended May 31, 2023, delivered revenues of C$6M, a 713% increase from the year ago quarter which was prior to the Novamind acquisition. Of greater significance, the company delivered double-digit sequential growth of 12.6%, highlighting the growth track in demand for its clinic and clinical research offerings. On this basis, revenues generated across Numinus’ wellness clinics in the US and Canada grew by 5.5% Q/Q, while its clinical ...

NUMI NUMINUS WELLNESS INC.
07/19/23 July 19, 2023 1 EN
Robert Sassoon
  • Robert Sassoon
NUMI NUMINUS WELLNES...

Water Tower Hour Recap : In Conversation with Numinus Founder & CEO Pa...

Payton Nyquvest joined The Water Tower Hour podcast and explained what inspired him to establish Numinus and his commitment to providing the much-needed infrastructure to support ongoing research in psychedelic-assisted therapies and to facilitate as broad-based patient access to psychedelic-assisted psychotherapies as is possible. Payton provides an overview of Numinus. He explains how the company is being positioned at the forefront of the revolution underway in the treatment of mental health ...

NUMI NUMINUS WELLNESS INC.
07/13/23 July 13, 2023 1 EN
Robert Sassoon
  • Robert Sassoon
NUMI NUMINUS WELLNES...

In the Driver's Seat for Prospective Rollout of MDMA-AT

Numinus extends collaboration with MAPS. Last week, Numinus announced a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) to support psychedelic experiential opportunities for practitioners as part of a clinical study, with permission to use MAPS’ protocol for the study. Numinus has submitted a clinical trial application (CTA) to Health Canada, which, if approved, will make the MDMA-AT experiential opportunity for practitioners available only through Numinus... WT...

NUMI NUMINUS WELLNESS INC.
06/20/23 June 20, 2023 1 EN
Robert Sassoon
  • Robert Sassoon
NUMI NUMINUS WELLNES...

Continuing on the Pathway to Success

Numinus participates in COMP360's landmark Phase III trial. It has been announced that Numinus' Cedar Clinical Research (CCR) is a participant in COMPASS Pathways' (CMPS) landmark COMP360 Phase III program investigating psilocybin-assisted therapy in treatment-resistant depression (TRD). The COMP360 Phase III studies, the first ever Phase III program of psilocybin therapy and the largest clinical study of a psychedelic compound, comprises two pivotal trials with an integrated long-term outcomes ...

NUMI NUMINUS WELLNESS INC.
05/31/23 May 31, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch